Aminosterol Dosing Protocol for Brain-Gut Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, autism spectrum disorder, depression, and constipation do not fully utilize the potential of aminosterols, particularly in terms of administration methods and dosage calibration, leading to suboptimal symptom management.
Innovation Solution
Administering aminosterols or their salts/derivatives through non-oral routes like nasal, sublingual, or intracerebroventricular methods, with a 'fixed dose' determination based on individual symptom response, escalating doses until improvement is observed, and maintaining that dose for sustained effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of aminosterols is used, then ease of operation is improved, but manufacturing precision of dosage is worsened due to difficulty in calibrating effective doses
Solution Approach 1:
The patent transforms the dosing parameter from fixed pre-determined amounts to dynamically adjusted doses based on individual patient response. The method involves administering escalating doses until symptom improvement is observed, then maintaining that specific dose level. This parameter change approach resolves the contradiction by making dosage calibration precise through iterative optimization rather than relying on predetermined standardized doses.
2Manufacturing precision
If non-oral administration routes are used, then dosage calibration precision is improved through direct delivery, but ease of operation is worsened due to complex administration procedures
Solution Approach 1:
The patent inverts the conventional approach by not requiring complex non-oral administration methods to achieve precision. Instead, it uses simple oral administration combined with iterative dose escalation and maintenance phases. This inversion resolves the contradiction by achieving dosage calibration precision through the treatment protocol rather than through complex administration routes.
3Ease of operation
If fixed doses are administered without individual calibration, then ease of operation is improved, but reliability of treatment effect is worsened due to variable patient responses
Solution Approach 1:
The patent applies dynamics by transitioning from static fixed dosing to a dynamic dosing protocol that adapts to individual patient responses. The treatment involves an escalation phase where doses are increased until improvement is observed, followed by a maintenance phase at that optimized dose level. This dynamic approach ensures reliability of treatment effect while maintaining ease of operation through systematic dose adjustment rather than complex individualized prescribing.
4Reliability
If escalating dose protocol is implemented, then reliability of treatment effect is improved through optimized dosing, but loss of time is worsened due to multiple dosing adjustments
Solution Approach 1:
The patent applies preliminary action by implementing a structured escalation protocol that proactively determines the optimal maintenance dose early in treatment. By systematically increasing doses at predetermined intervals and identifying the threshold for symptom improvement, the method establishes the effective dose sooner rather than later. This preliminary optimization reduces the overall time required for dose finding and minimizes the loss of time associated with trial-and-error dosing.
Data Source
AI summary
The present application relates generally to compositions and methods for treating and/or preventing a variety of symptoms and brain-gut disorders related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.